Navigation Links
Glimepiride in the medical management of Type 2 diabetes

Type 2 diabetes mellitus, a disorder of impaired insulin secretion and insulin resistance, has reached epidemic proportions.// The identification of high-risk individuals and lifestyle management can help control diabetes; however, most patients require pharmacologic intervention.

To achieve glycemic control, a stepwise treatment approach has generally been used, beginning with a program of diet and exercise, and to minimize the risk of future micro- and macrovascular complications.

Oral agents, with or without insulin, are added when diet and exercise fail to normalize glucose levels. Various pharmacologic agents are available for the management of Type 2 diabetes, including first- and second-generation sulfonylureas (glimepiride, glipizide, and glyburide), biguanides (metformin), á-glucosidase inhibitors (acarbose and miglitol), thiazolidinediones (pioglitazone and rosiglitazone), meglitinide analogues (repaglinide), amino acid D-phenylalanine derivatives (nateglinide), and insulin.

A recent article, presented in vol 18 (6) of Journal of Diabetes and its Complications reviews the role of the sulfonylureas - with a major focus on glimepiride, the newest of the second-generation sulfonylureas - in the medical management of Type 2 diabetes.

The sulfonylureas, the first oral agents introduced for the management of Type 2 diabetes, are effective, well-tolerated, and well-established drugs; Second-generation sulfonylureas are now widely used in the management of Type 2 diabetes. The most recent addition, glimepiride, can be used in combination with metformin, the thiazolidinediones, a-glucosidase inhibitors, and insulin. The unique properties of glimepiride may provide advantages over other currently available insulin secretagogues.

Type 2 diabetes mellitus can lead to serious long-term sequelae, such as blindness, kidney failure, heart disease, neurologic impairment, and stroke. Stringent lifestyle modifications, in cluding diet and exercise, are important measures in diabetes management, but they are often not sufficient to control hepatic glucose output and hyperglycemia.

The author, Stephen N. Davis, stresses that it is important to treat patients to the established target values for blood glucose and A1C to achieve and maintain normal glucose physiology.

Sulfonylureas are effective, well-tolerated drugs that have been used for decades. However, many of the original second-generation sulfonylureas are associated with hypoglycemia and weight gain and thus may not be appropriate for patients prone to hypoglycemia or for those who are overweight or renally impaired.

The investigation of glimepiride, the newest second-generation sulfonylurea, has led to the identification of several properties that may overcome some of these limitations. In addition, glimepiride has been found to effectively reduce PPG and FPG levels and A1C concentrations and has a good safety profile.

Medindia on Diabetes: Diabetes is a group of diseases with one thing in common - a problem with insulin. The problem could be that your body doesn't make any insulin, doesn't make enough insulin or doesn't use insulin properly.
'"/>




Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Children! Protecting them from medical mistakes
7. More information sought by patients on medical errors
8. SARS necessitates medical masks
9. Mini motor for micromedical applications
10. Avenues to opened for medical tourists following relaxation of visa regulations
11. Canadians flocking to India for quick and efficient medical treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
Breaking Medicine Technology: